On 08 November, representatives of the State Institute of Drugs and Good Practices (FSI ‘SID & GP’) took part in the workshop dedicated to automation of the pharmaceutical industry organized by the Ministry of Industry and Trade of the Russian Federation.
The modern pharmaceutical manufacture is placing exacting demands on product quality. At the same time, the interest of manufacturers with the priority to reduce production costs cannot be disregarded.
Alexey Alekhin, Director of the Department of Pharmaceutical and Medical Industry Development of Minpromtorg of Russia, said:
“Automation of processes allows to minimize process-related risks, to remove the human factor for the most part and, consequently, to secure high product quality. It is important to implement systems allowing for improvement of production performance, which will have an impact both on the competitive ability of the industry on the whole and on the competitive ability of products supplied not only to the Russian market, but exported abroad as well.”
The workshop saw speeches of experts representing Russian and foreign companies supplying equipment and manufacturing systems for pharmaceutical, biotech, chemical, and food industries. The experts shared with workshop participants their experience and best practices in automation of manufacture. Igor Falkovskiy, Head of Good Engineering Practices Department of FSI ‘SID & GP’, highlighted the topicality of finished dosage forms manufacture following the up-to-date standards from the GMP point of view.
Vladislav Shestakov, Director of FSI ‘SID & GP’, stated:
“Automation processes and explosive development of robotics technology are the reality which has become ingrained in our everyday lives. An in this regard, the pharmaceutical industry is one of the leaders. Here, the most innovative solutions have always been applied. Today, state-of-the-art technologies in the industry are on the front burner. We witness the growth potential and market interest in development of automation. Being an inspection authority, our Institute has exclusive expertise providing us with an opportunity to analyze the dynamics of development of the current manufacture of all types of dosage forms, including the most modern ones, as well as changes in the needs of manufacturers.”